GENEART Receives European Patent for Selective Evolution of Proteins
European Patent Office grants patent titled "Method for carrying out the selective evolution of proteins in vitro"
The patent constitutes the basis for a proprietary technology platform, which allows to significantly improve the efficiency and activity of protein-based therapeutics, vaccines and industrial enzymes. The new technology relies on a continuous one-step process where the generation and screening of protein variants run virtually simultaneously. The procedure allows identifying optimal variants of a protein from a considerably larger pool much quicker than with conventional multi-stage processes. Therefore, this procedure increases the probability of identifying the ideal protein variant, for example a strong-binding antibody for cancer therapy.
"We have reached another milestone for the extension of our proprietary technology portfolio in the field of Gene Evolution by being granted the European patent. It is our stated goal to not only offer our customers gene variants and gene libraries for screening experiments but, with the successful completion of this project, to also deliver the improved protein over the mid-term", explained Prof. Dr. Ralf Wagner, CEO of GENEART AG.
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.